References

[1] Grégory Thiabaud, Guangan He, Sajal Sen, † Kathryn A. Shelton, Wallace B. Baze, Luke Segura, Julie Alaniz, Ruben Munoz Macias, Greg Lyness, Alan B. Watts, Hyun Min Kim, Hyunseung Lee, Mi Young Cho, Kwan Soo Hong, Rick Finch,* Zahid H. Siddik,* Jonathan F. Arambula,* and Jonathan L. Sessler* “Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium texaphyrin as potential antitumor agents” Proc. Natl. Acad. Sci. USA 2020, 117 (13), 7021–7029. https://doi.org/10.1073/pnas.1914911117

[2] Timothy C. Johnstone,1 Ga Young Park,1 and Stephen J. Lippard1,2

[3] PLoS One. 2017; 12(10): e0184360

[4] Adv Pharm Bull. 2017 Sep; 7(3):339-348

[5] Rebecca McCall, Briana Burney, Zarana Patel,Jannet Kocerha, Jonathan L. Sessler, Kuppuswamy Arumugam, and Jonathan F. Arambula* “Dual targeting of the cancer antioxidant network with naphthoquinone annulated gold(I) N-heterocyclic carbene complexes” Chem. Sci. 2017, 8, 5918–5929. https://doi.org/10.1039/C7SC02153D

[6] https://www.who.int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action

[7] https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html

[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396775/ – 2019 publication

[9] https://www.wcrf.org/dietandcancer/bladder-cancer-statistics/

[10] https://www.wcrf.org/dietandcancer/prostate-cancer-statistics/

[11] Zyl B van, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocr Relat Cancer. 25(5):R303-R318. doi:10.1530/ERC-17-0336

[12] Gadducci et al. Journal of Ovarian Research (2019) 12:9

[13] GLOBOCAN 2018 Global Cancer Observatory. International Agency for Research on Cancer 2018 http://gco.iarc.fr/

[14] Gregory Thiabaud, Rebecca McCall,† Guangan He, Jonathan F. Arambula, Zahid H. Siddik, and Jonathan L. Sessler “Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator” Angew. Chem. Int. Ed. 2016, 128, 12816–12821. DOI: 10.1002/ange.201604236

[15] Yaguang Ren, Adam C. Sedgwick, Jingqin Chen, Gregory Thiabaud, Calvin V. Chau, Jusung An, Jonathan F. Arambula, Xiao-Peng He, Jong Seung Kim, Jonathan L. Sessler, and Chengbo Liu “Manganese(II) Texaphyrin: A Paramagnetic Photoacoustic Contrast Agent Activated by Near-IR Light” J. Am. Chem. Soc. 2020, 142 (38) 16156–16160. https://doi.org/10.1021/jacs.0c04387

[16] Sajal, Sen, Stephanie Hufnagel, Esther Y. Maier, Isaiah Aguilar, Jayaraman Selvakumar, Jennie E. DeVore, Vincent M. Lynch, Kuppuswamy Arumugam, Zhengrong Cui, Jonathan L. Sessler, and Jonathan F. Arambula “Rationally Designed Redox-Active Au(I) N-Heterocyclic Carbene: An Immunogenic Cell Death Inducer” J. Am. Chem. Soc. 2020, 142(49) 20536–20541. https://doi.org/10.1021/jacs.0c09753

[17] https://worldovariancancercoalition.org/wp-content/uploads/2018/10/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018.pdf

[18] https://www.wcrf.org/dietandcancer/ovarian-cancer-statistics/

[19] Sessler, J. L.; Murai, T.; Lynch, V.; Cyr, M. “An ‘Expanded Porphyrin’:  The Synthesis and Structure of a New Aromatic Pentadentate Ligand,” J. Am. Chem. Soc. 1988, 110, 5586-5588. DOI: 10.1021/ja00224a062

[20] Magda D, Miller RA. Motexafin gadolinium: A novel redox active drug for cancer therapy. Semin Cancer Biol. 2006;16(6):466-476. doi:https://doi.org/10.1016/j.semcancer.2006.09.002